[CytoReason in Startup News] CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale Its AI disease models and establish US hub in Cambridge, Massachusetts

CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO).

Read more here.